Skip to main content Skip to section navigation Skip to footer

XORTX Therapeutics Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • XRx-008 for Autosomal Dominant Polycystic Kidney Disease
    • XRx-101 for Coronavirus/COVID-19
    • XRX-225 for Type 2 Diabetic Nephropathy
    • Publications
  • Technology
  • News
    • Press Releases
    • Events
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Contact

Press Releases

News

News

  • Press Releases
  • Events
Feb 27, 2018 7:30am EST

XORTX Therapeutics Provides Corporate Update

Feb 22, 2018 7:30am EST

XORTX Therapeutics Appoints Dave Matthews CFO

Jan 29, 2018 7:30am EST

XORTX Therapeutics Announces Appointment of Allan Williams and Paul Van Damme

  • arrow_back
  • 1…
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
rss_feed News RSS
©2022 XORTX Therapeutics Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap